Biogen Inc.

TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement requirements. “Reimbursement decisions from private payers help determine whether a treatment is a real option for families,” said Claire Zlobin, Founder, Life With A Baby. “It's exciting to see that most p.

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease portfolio reflect its continued commitment to advancing innovation in Alzheimer's disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts.

Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.